Molecular Therapy — Nucleic AcidsMolecular BiologyPeer-reviewed journal article
Development of conditional-siRNA programmable riboswitch for targeting adverse cardiac remodeling
Priyanka GokulnathiD, Ane Miren SalvadoriD, Caleb Graham, Si‐ping HaniD, Guoping LiiD, Ramaswamy KannappaniD, Christopher AzzamiD, Michail SpanosiD, Lisa J. SchereriD, Palaniappan SethuiD, John J. RossiiD, William A. GoddardiD, Saumya DasiD
Abstract
Heart Failure (HF) remains a global epidemic and a significant healthcare burden, with an unmet need for novel therapies to target the preceding pathological hypertrophy in vulnerable patients. Here we report the development of novel conditional-siRNA (Cond- siRNA) constructs that are selectively activated by disease-specific RNA biomarkers to enable cell-specific inhibition of a target disease-causing RNA. We designed a Cond- siRNA that can be activated by nppa mRNA, upregulated specifically in CMs under pathological stress, to silence the key pro-hypertrophic gene calcineurin by the effector siRNA. In cellular models including neonatal rat ventricular myocyte (NRVM) and rat cardiomyocyte cell-line (H9C2), Cond-siRNA exhibited low baseline activity in the absence of the disease biomarker but achieved targeted calcineurin silencing upon nppa mRNA induction by phenylephrine (PE)-induced stress in a two-dimensional (2D) cell culture system and pressure overload in three-dimensional (3D) heart-on a chip system. NRVM transfection with the Cond-siRNA resulted in a decreased expression of calcineurin mRNA specifically after PE or pressure-overload treatment, but not after vehicle treatment, proving nppa mRNA-specific activation of the effector siRNA against calcineurin. Specificity was confirmed as Cond-siRNA did not significantly silence calcineurin in cardiac fibroblasts and T cells, lacking nppa expression. Reduced calcineurin protein levels and NFATc1 nuclear translocation correlated with decreased NRVM hypertrophy after PE treatment, confirming Cond-siRNAs efficacy. This study offers proof-of-concept for Cond-siRNA as a targeted therapy to mitigate hypertrophic progression, paving the way for novel HF treatments. One sentence summaryConditional-siRNA targeting adverse cardiac remodeling GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC="FIGDIR/small/633434v1_ufig1.gif" ALT="Figure 1"> View larger version (27K): org.highwire.dtl.DTLVardef@1b6532borg.highwire.dtl.DTLVardef@10e3836org.highwire.dtl.DTLVardef@8c839eorg.highwire.dtl.DTLVardef@1152883_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 1
- FWCI
- 0.30
- Field percentile
- 49th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- LncRNA Bigheart trans-activates gene expression in a feed forward mechanism that facilitates calcineurin-NFAT signaling in myocardial hypertrophy
Nicolò Mangraviti, Frank Rühle, … León J. De Windt·bioRxiv·Dec 11, 2023
- SIRT2 inhibition protects against cardiac hypertrophy and heart failure
Xiaoyan Yang, Hsiang‐Chun Chang, … Hossein Ardehali·eLifePeer-reviewed·Sep 20, 2023
- The mechanical regulation of RNA binding protein hnRNPC in the failing heart
F. Martino, N. M. Varadarajan, … G. Forte·bioRxiv·Aug 27, 2021
- Targeting of CIP4-Calcineurin Signalosomes Improves Cardiac Structure and Function After Myocardial Infarction
Anne‐Maj Samuelsson, Abraham L. Bayer, … Michael S. Kapiloff·bioRxiv·May 12, 2025
- Cellular Interplay and Cytokine Hierarchy Cause Pathological Cardiac Hypertrophy in RAF1-Mutant Noonan Syndrome
J. C. Yin, M. J. Platt, … B. G. Neel·bioRxiv·Mar 30, 2017
- Dissociation of disease phenotype and allele silencing in hypertrophic cardiomyopathy
Alexandra Dainis, Kathia Zaleta-Rivera, … Euan Angus Ashley·bioRxiv·Jun 12, 2019